VIRTUAL EVENT
This meeting will bring together scientists, therapeutic developers and patient representatives to focus on immunogenicity issues related to the systemic administration of AAV gene therapy products and identify solutions for those issues.
Catherine Zander, PhD will speak about SCB’s efforts to develop a common language or process for evaluating pre-existing adeno-associated virus (AAV) immunity prior to attempting treatment.